PhaseⅠ/ⅡTrial of Autologous Bone Marrow Derived Mesenchymal Stem Cells to Patients With Spinal Cord Injury. View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2011-2014

ABSTRACT

The study is a phase I/II trial designed to establish the safety and efficacy of intravenous combined with intrathecal administration of autologous bone marrow derived mesenchymal stem cells to patients with spinal cord injury. Detailed Description Spinal cord injury (SCI) is a traumatic disorder resulting in a functional deficit that usually leads to severe and permanent paralysis. Pharmacological and rehabilitation therapies to SCI get limited effect. Another promising therapeutic approaches for SCI is cellular transplantation. Cell types used in SCI therapy include Schwann cells, olfactory ensheathing cells and adult stem cells, such as neural stem cells, umbilical cord blood derived cells, mesenchymal stem cells (MSCs) or induced pluripotent stem cells. There are not yet conclusive evidences on which types of glial or adult stem cells are most effective in SCI treatment. MSC have been shown to promote anatomical and functional recovery in animal models of SCI by promoting tissue sparing ,axonal regeneration, and remyelination. Therapeutic effects of MSCs are primarily due to the secretion of soluble factors and the provision of extracellular matrix that provide protection and support repair. MSC are attractive candidates for transplantation into human patients because they can be easily harvested, expanded and banked, or derived directly from the patient allowing for autologous transplantation, obviating the need for immune suppression. The clinical translation of cellular transplantation strategies requires a safe and efficient means of cellular delivery. In animal models of SCI, the most common delivery is direct injection into the injury site, which allows a defined number of cells to be delivered, but risks further injuring the cord. Less invasive methods for cell delivery have been investigated, including intravascular delivery (intravenous (IV) and intra-arterial) and delivery into the cerebrospinal fluid (intrathecal). These minimally-invasive techniques decrease the risk to the patient and allow delivery of multiple cell doses. Maybe intrathecal administration is superior to IV delivery, cell engraftment and tissue sparing were significantly better after intrathecal delivery, but more researches are needed for get conclusion. More... »

URL

https://clinicaltrials.gov/show/NCT01446640

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3120", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The study is a phase I/II trial designed to establish the safety and efficacy of intravenous combined with intrathecal administration of autologous bone marrow derived mesenchymal stem cells to patients with spinal cord injury.\n\nDetailed Description\nSpinal cord injury (SCI) is a traumatic disorder resulting in a functional deficit that usually leads to severe and permanent paralysis. Pharmacological and rehabilitation therapies to SCI get limited effect. Another promising therapeutic approaches for SCI is cellular transplantation. Cell types used in SCI therapy include Schwann cells, olfactory ensheathing cells and adult stem cells, such as neural stem cells, umbilical cord blood derived cells, mesenchymal stem cells (MSCs) or induced pluripotent stem cells. There are not yet conclusive evidences on which types of glial or adult stem cells are most effective in SCI treatment. MSC have been shown to promote anatomical and functional recovery in animal models of SCI by promoting tissue sparing ,axonal regeneration, and remyelination. Therapeutic effects of MSCs are primarily due to the secretion of soluble factors and the provision of extracellular matrix that provide protection and support repair. MSC are attractive candidates for transplantation into human patients because they can be easily harvested, expanded and banked, or derived directly from the patient allowing for autologous transplantation, obviating the need for immune suppression. The clinical translation of cellular transplantation strategies requires a safe and efficient means of cellular delivery. In animal models of SCI, the most common delivery is direct injection into the injury site, which allows a defined number of cells to be delivered, but risks further injuring the cord. Less invasive methods for cell delivery have been investigated, including intravascular delivery (intravenous (IV) and intra-arterial) and delivery into the cerebrospinal fluid (intrathecal). These minimally-invasive techniques decrease the risk to the patient and allow delivery of multiple cell doses. Maybe intrathecal administration is superior to IV delivery, cell engraftment and tissue sparing were significantly better after intrathecal delivery, but more researches are needed for get conclusion.", 
    "endDate": "2014-06-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01446640", 
    "keywords": [
      "autologous bone marrow", 
      "Mesenchymal Stromal Cell", 
      "patient", 
      "spinal cord injury", 
      "phase I/II trial", 
      "safety", 
      "efficacy", 
      "intrathecal administration", 
      "bone marrow-derived mesenchymal stem cell", 
      "disorder", 
      "functional deficit", 
      "paralysis", 
      "rehabilitation therapy", 
      "limited effect", 
      "promising therapeutic approach", 
      "cellular transplantation", 
      "cell type", 
      "Schwann cell", 
      "olfactory ensheathing cell", 
      "adult stem cell", 
      "neural stem cell", 
      "umbilical cord", 
      "induced pluripotent stem cell", 
      "conclusive evidence", 
      "functional recovery", 
      "animal model", 
      "sparing", 
      "axonal regeneration", 
      "remyelination", 
      "therapeutic effect", 
      "Bodily Secretion", 
      "soluble factor", 
      "provision", 
      "extracellular matrix", 
      "protection", 
      "repair", 
      "attractive candidate", 
      "transplantation", 
      "human patient", 
      "autologous transplantation", 
      "immune suppression", 
      "clinical translation", 
      "efficient mean", 
      "cellular delivery", 
      "delivery", 
      "direct injection", 
      "injury site", 
      "defined number", 
      "cell", 
      "risk", 
      "cord", 
      "invasive method", 
      "cell delivery", 
      "intravascular delivery", 
      "cerebrospinal fluid", 
      "invasive technique", 
      "multiple cell", 
      "cell engraftment", 
      "conclusion"
    ], 
    "name": "Phase\u2160/\u2161Trial of Autologous Bone Marrow Derived Mesenchymal Stem Cells to Patients With Spinal Cord Injury.", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01446640"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00011.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.413435.4", 
        "type": "Organization"
      }
    ], 
    "startDate": "2011-10-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1016/j.neulet.2006.03.069", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000113563"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/stemcells.2006-0807", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021232747"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1705757", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037004549", 
          "https://doi.org/10.1038/sj.bmt.1705757"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ccm.0b013e3181f17c0e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044506596"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.brainres.2010.05.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046595674"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/brs.0b013e31819403ce", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051916092"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2174/157488811796575323", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069215837"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3171/spi/2008/8/2/153", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071084387"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01446640"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01446640'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01446640'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01446640'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01446640'


 

This table displays all metadata directly associated to this object as RDF triples.

106 TRIPLES      16 PREDICATES      83 URIs      68 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01446640 schema:about anzsrc-for:3053
2 anzsrc-for:3120
3 schema:description The study is a phase I/II trial designed to establish the safety and efficacy of intravenous combined with intrathecal administration of autologous bone marrow derived mesenchymal stem cells to patients with spinal cord injury. Detailed Description Spinal cord injury (SCI) is a traumatic disorder resulting in a functional deficit that usually leads to severe and permanent paralysis. Pharmacological and rehabilitation therapies to SCI get limited effect. Another promising therapeutic approaches for SCI is cellular transplantation. Cell types used in SCI therapy include Schwann cells, olfactory ensheathing cells and adult stem cells, such as neural stem cells, umbilical cord blood derived cells, mesenchymal stem cells (MSCs) or induced pluripotent stem cells. There are not yet conclusive evidences on which types of glial or adult stem cells are most effective in SCI treatment. MSC have been shown to promote anatomical and functional recovery in animal models of SCI by promoting tissue sparing ,axonal regeneration, and remyelination. Therapeutic effects of MSCs are primarily due to the secretion of soluble factors and the provision of extracellular matrix that provide protection and support repair. MSC are attractive candidates for transplantation into human patients because they can be easily harvested, expanded and banked, or derived directly from the patient allowing for autologous transplantation, obviating the need for immune suppression. The clinical translation of cellular transplantation strategies requires a safe and efficient means of cellular delivery. In animal models of SCI, the most common delivery is direct injection into the injury site, which allows a defined number of cells to be delivered, but risks further injuring the cord. Less invasive methods for cell delivery have been investigated, including intravascular delivery (intravenous (IV) and intra-arterial) and delivery into the cerebrospinal fluid (intrathecal). These minimally-invasive techniques decrease the risk to the patient and allow delivery of multiple cell doses. Maybe intrathecal administration is superior to IV delivery, cell engraftment and tissue sparing were significantly better after intrathecal delivery, but more researches are needed for get conclusion.
4 schema:endDate 2014-06-01T00:00:00Z
5 schema:keywords Bodily Secretion
6 Mesenchymal Stromal Cell
7 Schwann cell
8 adult stem cell
9 animal model
10 attractive candidate
11 autologous bone marrow
12 autologous transplantation
13 axonal regeneration
14 bone marrow-derived mesenchymal stem cell
15 cell
16 cell delivery
17 cell engraftment
18 cell type
19 cellular delivery
20 cellular transplantation
21 cerebrospinal fluid
22 clinical translation
23 conclusion
24 conclusive evidence
25 cord
26 defined number
27 delivery
28 direct injection
29 disorder
30 efficacy
31 efficient mean
32 extracellular matrix
33 functional deficit
34 functional recovery
35 human patient
36 immune suppression
37 induced pluripotent stem cell
38 injury site
39 intrathecal administration
40 intravascular delivery
41 invasive method
42 invasive technique
43 limited effect
44 multiple cell
45 neural stem cell
46 olfactory ensheathing cell
47 paralysis
48 patient
49 phase I/II trial
50 promising therapeutic approach
51 protection
52 provision
53 rehabilitation therapy
54 remyelination
55 repair
56 risk
57 safety
58 soluble factor
59 sparing
60 spinal cord injury
61 therapeutic effect
62 transplantation
63 umbilical cord
64 schema:name PhaseⅠ/ⅡTrial of Autologous Bone Marrow Derived Mesenchymal Stem Cells to Patients With Spinal Cord Injury.
65 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01446640
66 schema:sdDatePublished 2019-03-07T15:24
67 schema:sdLicense https://scigraph.springernature.com/explorer/license/
68 schema:sdPublisher Nd8e93cd661be4b80b6487d7de9bc9114
69 schema:sponsor https://www.grid.ac/institutes/grid.413435.4
70 schema:startDate 2011-10-01T00:00:00Z
71 schema:subjectOf sg:pub.10.1038/sj.bmt.1705757
72 https://doi.org/10.1016/j.brainres.2010.05.011
73 https://doi.org/10.1016/j.neulet.2006.03.069
74 https://doi.org/10.1097/brs.0b013e31819403ce
75 https://doi.org/10.1097/ccm.0b013e3181f17c0e
76 https://doi.org/10.1634/stemcells.2006-0807
77 https://doi.org/10.2174/157488811796575323
78 https://doi.org/10.3171/spi/2008/8/2/153
79 schema:url https://clinicaltrials.gov/show/NCT01446640
80 sgo:license sg:explorer/license/
81 sgo:sdDataset clinical_trials
82 rdf:type schema:MedicalStudy
83 Nd8e93cd661be4b80b6487d7de9bc9114 schema:name Springer Nature - SN SciGraph project
84 rdf:type schema:Organization
85 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
86 rdf:type schema:DefinedTerm
87 anzsrc-for:3120 schema:inDefinedTermSet anzsrc-for:
88 rdf:type schema:DefinedTerm
89 sg:pub.10.1038/sj.bmt.1705757 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037004549
90 https://doi.org/10.1038/sj.bmt.1705757
91 rdf:type schema:CreativeWork
92 https://doi.org/10.1016/j.brainres.2010.05.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046595674
93 rdf:type schema:CreativeWork
94 https://doi.org/10.1016/j.neulet.2006.03.069 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000113563
95 rdf:type schema:CreativeWork
96 https://doi.org/10.1097/brs.0b013e31819403ce schema:sameAs https://app.dimensions.ai/details/publication/pub.1051916092
97 rdf:type schema:CreativeWork
98 https://doi.org/10.1097/ccm.0b013e3181f17c0e schema:sameAs https://app.dimensions.ai/details/publication/pub.1044506596
99 rdf:type schema:CreativeWork
100 https://doi.org/10.1634/stemcells.2006-0807 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021232747
101 rdf:type schema:CreativeWork
102 https://doi.org/10.2174/157488811796575323 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069215837
103 rdf:type schema:CreativeWork
104 https://doi.org/10.3171/spi/2008/8/2/153 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071084387
105 rdf:type schema:CreativeWork
106 https://www.grid.ac/institutes/grid.413435.4 schema:Organization
 




Preview window. Press ESC to close (or click here)


...